Get the Stockscreener App
2.98
1.36%
0.04
Pre-market:
2.98
Nrx Pharmaceuticals Inc stock is traded at $2.98, with a volume of 179.70K.
It is up +1.36% in the last 24 hours and down -8.59% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.94
Open:
$2.93
24h Volume:
179.70K
Relative Volume:
0.72
Market Cap:
$58.12M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.745
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-7.17%
1M Performance:
-8.59%
6M Performance:
-15.58%
1Y Performance:
+27.90%
1-Day Range:
$2.90
$3.05
1-Week Range:
$2.89
$3.2193
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.98 | 62.61M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What drives NRx Pharmaceuticals Inc. stock priceBreakout stock performance - jammulinksnews.com
What analysts say about NRx Pharmaceuticals Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com
NRx Pharmaceuticals' Dual-Path Strategy for NRX-100: A Game-Changer in Suicidal Depression Treatment - AInvest
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Charts Dual-Path for NRX-100 - Yahoo Finance
What analysts say about NRx Pharmaceuticals Inc. Equity Warrant stockSuperior trading gains - jammulinksnews.com
Is NRx Pharmaceuticals Inc. a good long term investmentBreakthrough profits - Autocar Professional
Is NRx Pharmaceuticals Inc. Equity Warrant a good long term investmentRapid portfolio appreciation - jammulinksnews.com
NRx Pharmaceuticals Inc. Equity Warrant Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
What drives NRx Pharmaceuticals Inc. Equity Warrant stock priceOutstanding stock performance - jammulinksnews.com
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
NRx Pharmaceuticals: Pioneering Mental Health Innovation Through Clinical and Operational Synergy - AInvest
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment - TipRanks
NRx Pharmaceuticals (NASDAQ: NRXP) Positioning At The Forefront Of Next-Gen Treatment - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic - The Globe and Mail
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic - Yahoo Finance
Nrx Pharmaceuticals shares rise 1.23% after-hours after being added to Russell Microcap Growth Index. - AInvest
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics - Eastern Progress
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic - The Globe and Mail
NRx Pharmaceuticals Files for Commissioner's National Priority Voucher for Ketamine Treatment - AInvest
NRXP: Analyst Maintains 'Buy' Rating with Target Price Firm at $31 | NRXP Stock News - GuruFocus
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100) - Nasdaq
New FDA Fast-Track Program Could Accelerate Ketamine Depression Drug Approval by 10 Months - Stock Titan
New to The Street Show #673 Airs Nationwide on Bloomberg TVSaturday, June 21 at 6:30 PM EST Featuring FLOKI, NRX Pharmaceuticals (NASDAQ:NRXP), MUSQThe Music ETF (NYSE:MUSQ), Health In Tech (NASDAQ:HIT), and Vita Bella - Detroit Free Press
New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST - The Joplin Globe
NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners - financial-news.co.uk
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners - StreetInsider
NRx Pharmaceuticals Taps Top Biotech IR Firm ahead of Critical FDA Filings and Clinic Acquisitions - Stock Titan
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP) - Livingston Daily
NRX Pharmaceuticals: A Promising Investment with Innovative Growth and Strong Financial Outlook - TipRanks
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
NRx Pharmaceuticals CEO Set to Reveal Latest Advances at Major Neuroscience Investment Conference - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Quantisnow
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):